GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (XTER:EVT) » Definitions » Price-to-Funds-From-Operations

Evotec SE (XTER:EVT) Price-to-Funds-From-Operations : (As of Dec. 12, 2024)


View and export this data going back to 1999. Start your Free Trial

What is Evotec SE Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Evotec SE Business Description

Industry
Address
Essener Bogen 7, Manfred Eigen Campus, Hamburg, DEU, 22419
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Executives
Dr. Christian Wojczewski Board of Directors
Aurélie Dalbiez Board of Directors
Prof. Dr. Iris Löw-friedrich Supervisory Board
Dr. Craig Johnstone Board of Directors
Dr. Cord Dohrmann Board of Directors
Dr. Werner Lanthaler Board of Directors